loading page

Home-based testing as an approach to estimate influenza vaccine effectiveness in South Africa, 2022 -- a pilot study
  • +9
  • Jocelyn Moyes,
  • Mvuyo Makhasi,
  • Sibongile Walaza,
  • Ntombela P,
  • Fahima Moosa,
  • Anne von Gottberg,
  • Nicole Wolter,
  • Mignon du Plessis,
  • Hunt G,
  • Cawood C,
  • Erica Dueger,
  • Cheryl Cohen
Jocelyn Moyes
National Institute for Communicable Diseases

Corresponding Author:[email protected]

Author Profile
Mvuyo Makhasi
National Institute for Communicable Diseases
Author Profile
Sibongile Walaza
National Institute for Communicable Diseases
Author Profile
Ntombela P
National Institute for Communicable Diseases
Author Profile
Fahima Moosa
National Institute for Communicable Diseases
Author Profile
Anne von Gottberg
National Institute for Communicable Diseases
Author Profile
Nicole Wolter
National Institute for Communicable Diseases
Author Profile
Mignon du Plessis
National Institute for Communicable Diseases
Author Profile
Hunt G
BARC laboratories
Author Profile
Cawood C
Epicentre Health Research
Author Profile
Erica Dueger
Sanofi SA
Author Profile
Cheryl Cohen
National Institute for Communicable Diseases
Author Profile

Abstract

Background. Surveillance programmes for influenza and other respiratory pathogens are important to generate vaccine effectiveness (VE) estimates and to inform vaccine composition. We aimed to explore the feasibility and acceptability of home-based testing. Methods In 3/9 provinces in South Africa, we established a self-referral system for individuals aged ≥18 years with respiratory symptoms of ≤10 days duration. Following electronic consent, swab collection material was delivered to participants who also completed a questionnaire including self-reported vaccination status. Swabs were tested by PCR for influenza, respiratory syncytial virus (RSV) and SARS-CoV-2. A test negative methodology was used to estimate influenza VE. Results Of 1456 samples collected between 1 December 2021 and 31 August 2022, 73 (5%) tested positive for influenza, 38 (3%) tested positive for RSV and 394 (27%) for SARS-CoV-2. We subtyped 55% (40/73) of the influenza positive specimens; 16/40 (40%) were influenza A (A(H1N1)pdm09; 10/40 (25%)A (H3N2)) and all 14/40(35%) influenza B were B/Victoria. Only 20% (279/1451) of participants reported influenza-like illness case definition symptoms of fever and cough. Influenza vaccine coverage was 11% (157/1454). The overall influenza VE was 26% (95% confidence interval, -73%;69%). Of the completed acceptability questionnaires, 123/127 (97%) participants would make use of the service again. 36% (46/127) of enrolled participants were recruited through the testing centre’s webpage and 13% (17/127) through social media. Conclusions Home-based swabbing was feasible and acceptable. We were able to calculate an influenza VE, although a large sample size and verification of vaccine status may improve the VE estimate in the future.
06 Mar 2024Submitted to Influenza and other respiratory viruses
06 Mar 2024Submission Checks Completed
06 Mar 2024Assigned to Editor
21 Mar 2024Reviewer(s) Assigned
08 May 2024Review(s) Completed, Editorial Evaluation Pending
12 May 2024Editorial Decision: Revise Major
30 Jun 20241st Revision Received
12 Oct 2024Submission Checks Completed
12 Oct 2024Assigned to Editor
15 Oct 2024Editorial Decision: Accept